CE18 - Innovation biomédicale 2018

Nacre, a source of new drug candidates for osteoporosis – NADO

Nacre, a source of new drug candidates for osteoporosis

Nacre is not only a source of calcium but also a source of bioactive compounds on both bone anabolism and resorption, i.e. bone remodeling. Thus, we propose simultaneous preventive and therapeutic approaches by correcting calcium deficiency and modulating bone cellular activities.

Objectives and scientific hypotheses

Research hypothese:<br />Nacre is not only a source of calcium but also a source of bioactive compounds on both bone anabolism and resorption, i.e. bone remodeling. Thus, we propose simultaneous preventive and therapeutic approaches by correcting calcium deficiency and modulating bone cellular activities.<br />Objectives: The aims the NADO project are (i) to characterize nacre active compounds, (ii) specify their mechanism of action, and (iii) determine how effective they are using murine models of osteoporosis. Fully understanding these three still-unknown items represents an ambitious challenge, crucial for the development and the use of nacre compounds to reverse osteoporosis bone imbalance.

Work package 1: Active compounds in Nacre
The purpose of this WP is to identify nacre active compounds that will be tested in WP2.

Work package 2: Osteoanabolic and antiresorptive actions
The purpose of this WP is to specify the effects of nacre compounds on osteoblasts and osteoclasts activity.

Work package 3: Action on bone loss models
The objective of this WP is to test nacre compounds, which passed successfully WP2, on two murine bone loss models: i) the ovariectomised model of osteoporosis (OVX) and ii) the hind limb tail-unloading bone loss model (immobilization model). The action of nacre and nacre compounds will be compared to those of pure CaCO3 considered as source of calcium. Bone quality and quantity will be evaluated using micro-computerized tomography and Finite Element Analyses, dynamic histomorphometry, assessment of mechanical properties, and serum bone markers. Body composition will be evaluated by densitometry (DXA).

Jalon objectif 1 : validation de l’effet de la nacre sur la réduction de la perte osseuse
- Ageing (modèle souris âgées) : Une première étude montre qu’une supplémentation nutritionnelle en poudre de nacre accroît la masse trabéculaire osseuse chez des souris femelles âgées (22 mois). Une nouvelle expérience de supplémentation nutritionnelle, pendant trois mois cette fois-ci, s’est terminée fin novembre 2020 chez des souris âgées de 20 mois. L’exploitation des données et des échantillons récoltés est en cours.

- Ovariectomy : Une supplémentation nutritionnelle en poudre de nacre est plus efficace que le carbonate de calcium pur pour limiter la perte osseuse dans un modèle d’ostéoporose induite par ovariectomie (ménopause induite) chez les rates. Cette étude montre l’effet protecteur de la nacre sur l’os. (cf Poster en annexe : design de l’étude et résultats principaux).

Jalon objectif 2 : mécanismes d’action de la nacre
- Proteomic : l’analyse protéomique a été réalisé en comparant les protéines présentes dans les sérums du groupe Ovariectomie et dans ceux du groupe Ovariectomie + Nacre. L’analyse des données protéomiques met en évidence la présence de 13 protéines de rat dont les niveaux dans le sérum ont été modifiés par la présence de nacre dans l’aliment. De plus, certaines protéines issues de la nacre ont pu être retrouvées seulement dans les sérums du groupe Ovariectomie + Nacre. Nous poursuivons l’analyse de ces résultats à l’aide de la bioinformatique.

Nacre and its compounds can be used as a nutraceutical supplement and acute and chronic drug to prevent and reduce bone loss. Recently, management of osteoporosis has evolved to include combination therapies. Combination therapy associates an antiresorptive drug with another that stimulates the development of new bone. In our NADO project, we propose the development of a natural approach that will permit maintaining and restoring a good bone remodeling balance by simultaneously inhibiting osteoclast bone resorption and stimulating osteoblast bone formation. Nacre is a candidate for long-term use because of its combination of effects: calcium supplement, anti-resorptive and osteoanabolic compounds.
NADO will be the basis for potential lead to the development of innovative therapies for the prevention and treatment of bone pathologies. Knowledge of the nacre compounds and their action will allow the exploration of possible combination therapies with these candidate molecules.
As we have focused this project specifically on calcium and active compounds, we do recognise that further investigations are needed to check if there might be any possibility of synergy with vitamin D supplementation.

1. Nguyen K.D., Laroche N., Vanden Bossche A., Bertache Y., Linossier M.-T., Thomas M., Peyroche S., Normand M., Vico L., Rousseau M., Effect of mother-of-pearl feeding on bone loss due to ovariectomy in the rat, BIOMIN XV, 15th International Symposium on Biomineralization, September 9-13, Munich, Germany, 2019. Oral
2. Nguyen K.D., Laroche N., Vanden Bossche A., Bertache Y., Linossier M.-T., Thomas M., Peyroche S., Normand M., Vico L., Rousseau M., Feeding powdered nacre prevents ovariectomy-induced bone loss in rats, 47th European Calcified Tissue Society Congress (Digital), October 22-24, Marseille, France, 2020. Poster en annexe
3. Laquerriere P., Jessel B., Laroche N., Malaval L., Vanden-Bossche A., Linossier M.-T., Thomas M., Normand M., Vico L., Rousseau M., The influence of nacre nutritional supplementation on bone preservation in aged mice, 46th European Calcified Tissue Society Congress, 11-14 may, Budapest, Hungary, 2019. Poster
4. Jessel B., Laroche N., Thomas M., Linossier M.-T., Normand M., Vanden-Bossche A., Vico L., Laquerriere P., Rousseau M., Une supplémentation nutritionnelle en poudre de nacre accroît la masse trabéculaire osseuse chez des souris âgées, 21èmes JFBTM, 5-7 juin, Boulogne-sur-mer, France, 2019. Oral

Nacre is a natural composite that has the ability to stimulate bone formation via osteoblasts and to reduce bone resorption mediated by osteoclasts. The exact composition of nacre remains until now unknown and the structure and nature of the active components are partially known. This project will be divided in three parts:
1. We will continue the identification and synthesis of the active peptides of nacre.
2. We will specify how nacre molecules act on osteoblastic stimulation and osteoclastic inhibition. First, we will screen the activity of the nacre molecules identified in step 1, then we will analyse the signaling pathways activated in osteoblasts and osteoclasts.
3. Finally, we will determine the ability of nacre and its compounds to limit bone loss in the hindlimb unloaded and ovariectomized mice models.
The results will represent a decisive breakthrough allowing new developments in therapeutics to reverse osteoporosis bone imbalance.

Project coordination

Marthe Rousseau (SAnté INgenierie BIOlogie Saint-Etienne)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partnership

SAINBIOSE SAnté INgenierie BIOlogie Saint-Etienne

Help of the ANR 252,288 euros
Beginning and duration of the scientific project: December 2018 - 48 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter